

Is Esperoct® right for you?

It's time to change the conversation
about hemophilia A treatment



WHAT IS ESPEROCT®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

- Esperoct® is not used to treat von Willebrand Disease

IMPORTANT SAFETY INFORMATION

Who should not use Esperoct®?

- You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

Please see additional Important Safety Information throughout.
Please see accompanying Prescribing Information.



esperoct®

*antihemophilic factor (recombinant),
glycopegylated-exei*

When it comes to choosing your factor, you have a voice!

Finding a hemophilia A treatment to fit your lifestyle is important. Use this brochure to determine which features of a treatment matter most to you. Share those results with your health care provider and get the conversation started about why Esperoct® may be the right fit for you.



Having a treatment that provides high factor levels for a longer time is important to me.

Strongly disagree Disagree Neutral Agree Strongly agree

I want to dose less frequently.

Strongly disagree Disagree Neutral Agree Strongly agree



The safety of my factor is an important consideration in my decision to change treatment.

Strongly disagree Disagree Neutral Agree Strongly agree



I want a factor that I can take with me, without refrigeration, even at high temperatures (up to 104°F).

Strongly disagree Disagree Neutral Agree Strongly agree



I want to know that the company that makes my factor is committed to supporting me.

Strongly disagree Disagree Neutral Agree Strongly agree

Other important things about my treatment: _____

Notes/questions for my health care provider: _____

How Esperoct® can help you move beyond the threshold.^a

^aOf 1% trough factor levels for SHL products in adults and adolescents.

Here's why

Prophylaxis

Fewer infusions per year compared with SHL dosing regimens in adults and adolescents

- 50% fewer infusions if previously infused every other day
- 40% fewer infusions if previously infused 3x/week

High factor levels in adults and adolescents

- At or above 3% for 100% of the time^{b,c}
- At or above 5% for 90% of the time^{b,d}

^bTrough level goal is 1% for prophylaxis.

^cData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.

^dSteady-state factor VIII activity levels were estimated in 143 adults and adolescents using PK modeling.

The largest and longest EHL clinical trial program

- Proven in previously treated patients

Flexible on the go

- The only EHL product that can be stored at 104°F for up to 3 months or can be stored up to 86°F for up to 12 months
- Can be stored within 4 hours after reconstitution at up to 86°F

Novo Nordisk, the maker of Esperoct®, is committed to helping the bleeding disorders community, with over 30 years of research, clinical experience, and support for people with bleeding disorders and their health care providers.

EHL=extended half-life; PK=pharmacokinetic; SHL=standard half-life.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about Esperoct®?

- Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
- Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

Please see additional Important Safety Information throughout. Please see accompanying Prescribing Information.

esperoct®
antihemophilic factor (recombinant),
glycopegylated-exei

We're here to support you

Trial program

Visit **MYNOVOSECURE.COM** or call **1-844-NOVOSEC (1-844-668-6732)** to speak with a NovoSecure™ Specialist to find out if you're eligible to receive a limited supply of Esperoct® for free^a

^aPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.



Share your brochure results with your health care provider and get the conversation started about Esperoct® today!



Be sure to visit Esperoct.com for more information.

IMPORTANT SAFETY INFORMATION

What should I tell my healthcare provider before using Esperoct®?

- Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called "inhibitors" against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®

What are the possible side effects of Esperoct®?

- Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please see additional Important Safety Information throughout.

Please see accompanying Prescribing Information.

Esperoct® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536 U.S.A.

Esperoct® is a registered trademark and NovoSecure™ is a trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2020 Novo Nordisk Printed in the U.S.A. US19ESP00085 January 2020



esperoct®
*antihemophilic factor (recombinant),
glycopegylated-exei*